Evidence map›Paper›PMID 38269058›Full record

ArticleLymphatics2023

What is Next in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.

Aimee C Talleur, Ching-Hon Pui, Seth E Karol

Abstract read
In one paragraph

Article in Lymphatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aimee C TalleurDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Seth E KarolDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Hypertension Intervention to Reduce Osteonecrosis in Children with Acute Lymphoblastic LeukemiaK08CA250418 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KAROL, SETH EVAN · 2020 to 2024
$1.1M
NCI NIH HHS K08 CA250418NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

Cure rates now exceed 90% in many contemporary trials for children with B-cell acute lymphoblastic leukemia (ALL). However, treatment remains suboptimal and therapy is toxic for all patients. New treatment options potentially offer the chance to reduce both treatment resistance and toxicity. Here, we review recent advances in ALL diagnostics, chemotherapy, and immunotherapy. In addition to describing recently published results, we also attempt to project the impact of these new developments into the future to imagine what B-ALL therapy may look like in the next few years.

Indexed as

acute lymphoblastic leukemiachildhoodtreatment

Identifiers

PMID38269058
PMCPMC10804398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.